[go: up one dir, main page]

WO2018085794A1 - Formulations de cannabinoïdes thérapeutiques et procédés pour leur utilisation - Google Patents

Formulations de cannabinoïdes thérapeutiques et procédés pour leur utilisation Download PDF

Info

Publication number
WO2018085794A1
WO2018085794A1 PCT/US2017/060248 US2017060248W WO2018085794A1 WO 2018085794 A1 WO2018085794 A1 WO 2018085794A1 US 2017060248 W US2017060248 W US 2017060248W WO 2018085794 A1 WO2018085794 A1 WO 2018085794A1
Authority
WO
WIPO (PCT)
Prior art keywords
topical formulation
skin
formulation according
cannabinoid
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/060248
Other languages
English (en)
Inventor
Margaret M. Gardner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avidas Pharmaceuticals LLC
Original Assignee
Avidas Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidas Pharmaceuticals LLC filed Critical Avidas Pharmaceuticals LLC
Priority to US16/347,587 priority Critical patent/US20190255014A1/en
Priority to CA3081755A priority patent/CA3081755A1/fr
Publication of WO2018085794A1 publication Critical patent/WO2018085794A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Definitions

  • Topical deliveries of ingredients intended to protect and/or enhance the skin's appearance are intended to be delivered to the top of the skin and not transdermally.
  • labeling of cosmetics and skin protecting ingredients advise that these ingredients should not be applied on broken skin, deep puncture wounds or serious burns.
  • Their function is to largely to protect skin from damage such as external damage (wind, cold, UV radiation, etc), reactive oxygen species (peroxides, superoxides, oxidative stress), inflammation and intrinsic aging (cutaneous aging of the skin), to provide relief to conditions such as redness, rashes, chapping, chaffing, bites, cuts, scrapes, etc and improve the appearance of skin.
  • Cosmetic ingredients to improve the condition and appearance of skin are well established and can be found in the Personal Care Products International Nomenclature of Cosmetic Ingredients. Examples of such cosmetic ingredients include emollients and conditioning agents.
  • inventive compounds are useful for treating and improving symptoms and side effects of disorders and diseases including but not limited to auto-immune and auto-immune related disorders, cancer,
  • the instant invention includes methods for treating the symptoms and side effects of disorders, diseases and the symptoms and the side effects of their treatments including but not limited to auto-immune and auto-immune related disorders, cancer,
  • osteoarthritic/muscoloskeletal disorders comprising administering a composition of the instant invention.
  • the invention is directed to topical formulations, including (a) a therapeutically effective amount of at least one cannabinoid compound; (b) at least one skin protecting/enhancing ingredient; and (c) a pharmaceutical carrier effective for simultaneous transdermal delivery of the at least one cannabinoid compound and topical delivery of the skin protecting/enhancing ingredient.
  • the pharmaceutical carrier does not include lecithin or soy- based ingredients or harsh irritating penetration enhancers.
  • the antioxidant is 0 ⁇ % to about 20%, 0 ⁇ % to about 5%, about 1% to about 5%, about 2% to about 5%, about 3% to about 5%, about 4% to about 5%, about 5% to about 9%, about 5% to about 8%, about 5% to about 7%, about 5% to about 6%, about 3% to about 4%, about 3% to about 10%, about 3% to about 1 1%, about 3% to about 12%, about 3% to about 13%, about 3% to about 14%, about 3% to about 15%, about 3% to about 16%, about 3% to about 17%, about 3% to about 18%, about 3% to about 19%, about 3% to about 20%, or about 5% to about 20% of the topical formulation.
  • the at least one cannabinoid compound is present in an amount therapeutically effective to improve the symptoms and side effects of disorders, diseases and their relative treatments' side effects and symptoms.
  • the skin protecting/enhancing agent is present in an amount effective to prevent, treat skin conditions and/ or enhance the appearance of skin.
  • the skin condition is selected from the group consisting of external skin damage, skin damage resulting from reactive oxygen species, chemicals, drug therapies, radiation, skin irritants, inflammation, cutaneous skin aging, rashes, chapping, chaffing, bites, burns, cuts, and scrapes.
  • the pharmaceutical carrier includes a wetting
  • the instant invention includes methods for preventing, treating skin conditions and/or enhancing the appearance of skin such as the prevention of premature aging, skin cancer, dry skin, skin irritations such as rashes, chapping, chaffing, bites, cuts, scrapes, abrasions, erythema, minor burns, etc. comprising administering a composition of the instant inventions.
  • the compositions in any embodiment of the present invention may be topically administered to a mammal in a single application, or may be topically administered to a mammal in multiple applications.
  • the inventive formulations include cannabinods in specific therapeutic amounts for treating mammals suffering from disorders, diseases and their symptoms and side effects including but not limited to auto-immune and auto-immune related disorders, cancer, osteoarthritic/muscoloskeletal disorders,
  • the inventive formulations include cannabinods in specific therapeutic amounts for treating mammals suffering from the symptoms and side effects of treatments for disorders and diseases including but not limited to auto-immune and auto-immune related treatments, cancer and radiation treatments, osteoarthritic/muscoloskeletal treatments, inflammation, fatigue, nausea, muscle and/or joint symptoms, pain, anxiety and paranoia, loss of appetite and seizures, while simultaneously preventing, treating skin conditions and/or improving the appearance of their skin.
  • treatments for disorders and diseases including but not limited to auto-immune and auto-immune related treatments, cancer and radiation treatments, osteoarthritic/muscoloskeletal treatments, inflammation, fatigue, nausea, muscle and/or joint symptoms, pain, anxiety and paranoia, loss of appetite and seizures, while simultaneously preventing, treating skin conditions and/or improving the appearance of their skin.
  • a "therapeutically effective amount" of cannabinoid present in the inventive cannabinoid formulations is one in which improvement is realized in symptom or side effects with respect to one or more disorders, disease states and/or associated treatments in an mammal.
  • symptoms and side effects include, for example and without limitation, symptoms and side effects of all known disease states, disorders and associated treatments regardless of whether environmental, genetic, lifestyle, physical activity, dietary and/or physiological factors.
  • a "therapeutically effective amount" of cannabinoid present in the inventive formulations is one in which a specific amount of cannabinoid(s) is administered transdermally into the skin of an individual, in order to penetrate the skin for improve the appearance and health of the skin and/or transdermally to enter the blood stream.
  • inventive formulations include skin protecting/enhancing ingredients, ingredients that prevent, treat skin conditions and/or enhance the appearance and are intended to remain mostly on the top of the skin
  • achieving a therapeutically effective amount of cannabinoid will take into account various factors attendant to the skin protecting/ enhancing ingredients, for example and without limitation, that such formulations may be exposed to water (including alkaline salt water), may be partially removed by "towel drying" after a period of time, and so forth, and therefore in such embodiments such factors may be taken into account to ensure that a therapeutically effective amount of cannabinoid is administered to the individual, for example and without limitation, the concentration of cannabinoid, the delivery mechanism, and the inclusion of specific ingredients such as stabilizers, waterproofing agents, and so forth.
  • inventive formulations include one or more skin protecting/enhancing ingredients
  • exemplary ingredients include allantoin, aluminum hydroxide gel, calamine, cocoa butter, cod liver oil, vitamin A, cannabinoids, cholecalciferol, colloidal oatmeal, dimethicone, emollients, glycerin, hard fat, kaolin, lanolin, mineral oil, vegetable oils, plant oils, petrolatum, skin conditioning agents, sodium bicarbonate, topical starch, white petrolatum, zinc acetate, zinc carbonate, zinc oxide and derivatives, combinations, and mixtures thereof.
  • the skin protecting/enhancing ingredients in the inventive formulation include sun protecting ingredients.
  • the inventive formulations may include UV radiation absorbers (sunscreen filters).
  • polyethylene glycol polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6, -hexanetriol, ethoxylated glycerol, propoxylated glycerol, and derivatives,
  • the inventive formulations may include preservatives, such as methylparaben, ethylparaben, butylparaben, propylparaben, phenoxyethanol, dmdm hydantoin, natural preservatives and derivatives, combinations, and mixtures thereof.
  • preservatives such as methylparaben, ethylparaben, butylparaben, propylparaben, phenoxyethanol, dmdm hydantoin, natural preservatives and derivatives, combinations, and mixtures thereof.
  • the inventive formulations may include anti-irritant agents, such as allantoin, aloe, licorice extract, aloe, bisabolol, colloidal oatmeal, curcumin, petrolatum, ubiquinone and derivatives, combinations, and mixtures thereof.
  • anti-irritant agents such as allantoin, aloe, licorice extract, aloe, bisabolol, colloidal oatmeal, curcumin, petrolatum, ubiquinone and derivatives, combinations, and mixtures thereof.
  • inventive formulations may also include mixtures and combinations and any of the above.
  • inventive formulation may have an SPF of about 2 to about 95, and in certain exemplary, non-limiting embodiments have an SPF of greater than 95. It is understood that the inventive formulations are not limited to any particular SPF or SPF range, and formulations having any SPF are contemplated in the present invention.
  • the amount of cannabinoid necessary to achieve a desired therapeutic result is influenced by, and will therefore vary based on, a number of factors, including for example and without limitation, the age, sex, and weight of the mammal, factors that influence the metabolic rate, and the specific disorders, diseases or related treatment symptoms of the mammal.
  • the amount of at least one cannabinoid in the inventive formulation is between about 0.01% and about 25%.
  • the composition provides an individual dose of about 20 mg of cannabinoid.
  • the aqueous solution used to hydrate the lipophilic phase in forming the transdermal carrier may be in certain embodiments, a physiologically compatible solution such as water.
  • the aqueous solution may have an active agent dissolved in it.
  • the basic procedure according to this invention is to mix the wetting/emulsifier ingredients and antioxidant(s) (e.g., tocopherol, tocotrienol or mixtures thereof) to form a lipophilic phase.
  • antioxidant(s) e.g., tocopherol, tocotrienol or mixtures thereof
  • Non-phospholipid lipids or mixtures thereof e.g.
  • the transdermal delivery involves the application of the instant invention to the mammal' s skin.
  • a number of methods known in the art can be used to assess cannabinoids therapeutic effect. In one method, delivery may be assessed by measuring pain relief.
  • a well-known method of testing topical skin-protecting ingredients known in the art is sunscreen testing efficacy.
  • Skin Protecting/Enhancing Ingredient about 25% to about 46% Skin Protecting/Enhancing Ingredient about 26% to about 47%
  • Aqueous Component about 35% to about 99%
  • Aqueous Component about 55% to about 95%
  • Aqueous Component about 58% to about 95%
  • Aqueous Component about 65% to about 95%
  • Aqueous Component about 80% to about 95%
  • Aqueous Component about 55% to about 60%
  • Aqueous Component about 55% to about 65%
  • Aqueous Component about 55% to about 70%
  • Aqueous Component about 55% to about 75%
  • Aqueous Component about 55% to about 80%
  • Aqueous Component about 55% to about 85%
  • Aqueous Component about 65% to about 90%
  • Antioxidant or Mixture 0 ⁇ % to about 20%
  • Antioxidant or Mixture 0 ⁇ % to about 5%
  • Antioxidant or Mixture about 1% to about 5%
  • Antioxidant or Mixture about 2% to about 5%
  • Antioxidant or Mixture about 4% to about 5%
  • Antioxidant or Mixture about 5% to about 8%
  • Antioxidant or Mixture about 5% to about 6%
  • Antioxidant or Mixture about 3% to about 4%
  • Antioxidant or Mixture about 3% to about 10% Antioxidant or Mixture about 3% to about 11%
  • Antioxidant or Mixture about 3% to about 13%
  • Antioxidant or Mixture about 3% to about 14%
  • Antioxidant or Mixture about 3% to about 15%
  • Antioxidant or Mixture about 3% to about 19%
  • Antioxidant or Mixture about 3% to about 20%
  • the cannabinoid compounds may be greater than 25% of the topical formulation.
  • the therapeutically effective cannabinoid improves energetic effects concurrently while the skin protecting/enhancing agent(s) which, when applied topically, permits the more energetic mammal to engage in outdoor activity while reducing or eliminating skin damage resulting from environmental exposure (damage from UVA and/or UVB rays, and/or wind and/or cold, etc).
  • This reduced skin damage is beneficial to mammals with autoimmune diseases or disorders and/or mammals being treated for auto-immune diseases or disorders where the disease or disorder and/or treatments result in fatigue and lack of energy as well as photosensitive and compromised skin, and thus these inventive formulations are provided with concurrent transdermal administration of cannabinoid(s) and topical administration of skin protecting/enhancing agent(s) to compensate for the multiple symptoms and side effects associated with the disease or disorder.
  • inventive formulations may be provided for use by a number of mammals engaged in varied activities and using these inventive formulations under varied conditions, while in all cases simultaneously delivering cannabinoid transdermally while topically preventing, treating skin conditions and/or enhancing the skin in such mammals.
  • the choice of cannabinoid agent(s) will depend on a number of factors, including the age, weight, severity of side effects and symptoms, including, for example symptoms and side effects of cancer and/or cancer treatments, (including, for example pain and chemotherapy and/or radiation induced skin irritation).
  • the inventive formulation provides a therapeutically effective amount cannabinoid that is administered transdermally to relieve pain, while providing skin protection/enhancement to compromised skin caused by the disorder, disease and/or caused by the relevant treatment for the disorder.
  • inventive treatment formulations may be provided for use by a number of mammals engaged in varied activities and using these inventive treatment formulations under varied conditions, while in all cases delivering therapeutic amounts of cannabinoid for pain while providing skin protection/enhancement such as relief for skin irritations and/or improved appearance of skin caused by harmful effects of radiation, environmental, chemicals, drug therapies and other skin irritants.
  • Example 3 Skin Protecting/Enhancing Cannabinoid Formulations for Treating the Symptoms of Disorders, Diseases and their Relevant Treatments for Severe Chronic
  • a cannabinoid formulation without the need for phospholipids or harsh irritating penetration enhancers is prepared according to the present invention to have at least one cannabinoid compound present in a therapeutically effective amount; at least one skin protecting/enhancing agent; and a bimodal pharmaceutical carrier for improving the symptoms and side effects of severe chronic diseases.
  • disorders and/or diseases which may be treated using the inventive formulations include, for example and without limitation, disorders and diseases and their relative treatments associated with autoimmune disorders and diseases, autoimmune and auto-immune related disorders, cancer, osteoarthritic/muscoloskeletal disorders, infectious disease sequella, psychological and neurological disorders, inflammation, fatigue, nausea, muscle and/or joint symptoms, pain, anxiety and paranoia, loss of appetite, spasms and seizures.
  • the choice of cannabinoid and skin protecting/enhancing agent(s) will depend on a number of factors, including the desired symptom relief of the resulting inventive formulation. For example, a higher amount of cannabinoid may be desired by individuals with pain compared to individuals with a loss of appetite; a higher amount of skin protecting/enhancing ingredients may be desired by individuals who desire skin protecting/enhancing ingredients that do not minimize or eliminate, UVA and/or UVB exposure as the area of the body for the product application will not be exposed to UVA/UVB radiation. For example osteoarthritic joint pain may require a cannabinoid like CBD that has shown efficacy data in treating inflammation and arthritis. As the product may be applied directly to the joint to benefit from a local effect, the skin protecting/enhancing ingredients may be zinc oxide or allantoin for their anti-irritant benefits.
  • the inventive formulation provides a therapeutically effective amount cannabinoid that is administered transdermally to relieve pain, while providing relief to skin irritation caused by the disorder, disease and/or relevant treatment.
  • inventive treatment formulations may be provided with specific concentration of cannabinoid combined with skin protecting/enhancing ingredients, and other ingredients, selected for each inventive formulation based on the specific intended use of the resulting inventive formulation, including the environmental and other conditions in which the inventive formulation is intended to be used, and whether the inventive formulation is intended to be pre-applied or re-applied after particular activities and/or after specific periods of time, and also taking into account specific characteristics of the mammal for whom it is intended that may impact cannabinoid delivery in such mammal.
  • Example 4 Formulations.
  • EAE encephalomyelitis
  • cannabinoids and oral mucosal cannabinoids have been used for medical treatments including Multiple Sclerosis (MS) in humans); Zettl, et al. "Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.” Ther. Adv. Neurol. Disord. 2016 Jan;9(l):9-30 (reporting THC-CBD efficacy and effectiveness for spacitity with oromucosal spray in humans); Reznik, et al. "Cannabidiol: a potential treatment for post Ebola syndrome?" Int. J. Infect. Pis.
  • a lipohilic composition of 28 grams (14% w/w) of wetting/emulsifying ingredient combined with antioxidants are mixed.
  • the aqueous solution is used to hydrate the lipophilic phase.
  • 6 grams (3% w/w) of CBD are added to the mixture.
  • a composition of skin protecting/enhancing ingredients 10 grams (5% w/w) are added to the aqueous and lipophilic mixture and mixed. Once thoroughly mixed, preservatives (1% w/w), antioxidants and viscosity adjusters (2% w/w) are added.
  • the formulation included the active ingredient cannabidiol and active skin protecting/enhancing ingredients in a carrier to deliver the cannabidiol transdermally and the skin protecting/enhancing ingredients topically.
  • the inclusion criteria for the study was subjects suffering from mild, moderate or severe pain. The subjects were asked to identify the site of their pain and indicate their baseline pain using the universal pain assessment tool (Scale of 1-10). Subjects applied one gram of the cannabidiol (CBD) formulation to the site of the pain or asked to apply to the wrists for overall pain.
  • CBD cannabidiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations qui permettent l'administration transdermique de cannabinoïde(s) en des quantités thérapeutiquement efficaces sans nécessiter de phospholipides ou des promoteurs de pénétration irritants difficiles tout en administrant simultanément des ingrédients de protection/amélioration de la peau par voie topique sur la partie supérieure de la peau pour prévenir et traiter des affections cutanées et/ou améliorer l'aspect de la peau.
PCT/US2017/060248 2016-11-07 2017-11-06 Formulations de cannabinoïdes thérapeutiques et procédés pour leur utilisation Ceased WO2018085794A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/347,587 US20190255014A1 (en) 2016-11-07 2017-11-06 Therapeutic Cannabinoid Formulations and Methods for Their Use
CA3081755A CA3081755A1 (fr) 2016-11-07 2017-11-06 Formulations de cannabinoides therapeutiques et procedes pour leur utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662418756P 2016-11-07 2016-11-07
US62/418,756 2016-11-07

Publications (1)

Publication Number Publication Date
WO2018085794A1 true WO2018085794A1 (fr) 2018-05-11

Family

ID=62076495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/060248 Ceased WO2018085794A1 (fr) 2016-11-07 2017-11-06 Formulations de cannabinoïdes thérapeutiques et procédés pour leur utilisation

Country Status (3)

Country Link
US (1) US20190255014A1 (fr)
CA (1) CA3081755A1 (fr)
WO (1) WO2018085794A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028875A1 (fr) * 2018-08-02 2020-02-06 DIVIOS, LLC (a California Limited Liability Company) Composition d'écran solaire renfermant des extraits de cannabis
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
CN111297711A (zh) * 2020-02-17 2020-06-19 植物医生(广东)生物科技有限公司 一种大麻二酚在制备具有舒缓抗刺激功效的护肤制品、保健品或食品中的应用
WO2021016612A1 (fr) * 2019-07-25 2021-01-28 Hempvana, Llc Médicament enrobé de chanvre ou d'un autre cannabinoïde
WO2021116808A1 (fr) * 2019-12-10 2021-06-17 Avicanna Inc. Composition topique de soin de la peau et méthodes de traitement de l'eczéma
US11147777B1 (en) 2017-06-16 2021-10-19 Charlotte's Web, Inc. Methods and formulations for efficacious pain relief by transdermal delivery of cannabidiol
US20220257482A1 (en) * 2018-01-13 2022-08-18 TRUETIVA, Inc. Anti-aging and skin tone lightening compositions and methods for same
WO2023053043A1 (fr) * 2021-09-28 2023-04-06 Impactive Holdings Ltd. Compositions topiques à base de cannabinoïdes pour soulager la douleur
WO2023105226A1 (fr) * 2021-12-07 2023-06-15 Vive Skincare Limited Compositions de soins de la peau
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CA3156257A1 (fr) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. Administration transdermique de dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
AU2020361741B2 (en) 2019-10-11 2024-09-05 Pike Therapeutics Inc. Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CN111557900B (zh) * 2020-05-22 2023-05-12 广州大洲生物医药科技有限公司 大麻二酚乳膏剂，其制备方法及用途
US20220125696A1 (en) * 2020-10-25 2022-04-28 John Christian Haught Inflammation reducing composition containing a cannabis sativa compound
WO2022149144A1 (fr) * 2021-01-11 2022-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Préparations cosmétiques stables et efficaces
WO2023003968A1 (fr) * 2021-07-20 2023-01-26 Enveric Biosciences, Inc. Compositions pour le traitement topique de la dermatite rayonnante
US12059393B2 (en) 2022-02-11 2024-08-13 Akos Biosciences, Inc. Compositions for topical treatment of radiation dermatitis
CN116035929B (zh) * 2023-01-04 2023-08-29 宝萃生物科技有限公司 一种姜黄素脂质体及其制备和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202891A1 (en) * 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
US20120264818A1 (en) * 2011-04-15 2012-10-18 Jon Newland Topical Compositions with Cannabis Extracts
US20150297653A1 (en) * 2014-04-17 2015-10-22 Gary J. Speier Pharmaceutical composition and method of manufacturing
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102296A2 (fr) * 2004-04-23 2005-11-03 Heptagen Limited Associations pour traiter des troubles cutanes immunoproliferatifs
US8470304B2 (en) * 2009-08-04 2013-06-25 Avidas Pharmaceuticals Llc Therapeutic vitamin D sun-protecting formulations and methods for their use
JP2013503206A (ja) * 2009-08-31 2013-01-31 オールトランツ インコーポレイティド マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202891A1 (en) * 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
US20120264818A1 (en) * 2011-04-15 2012-10-18 Jon Newland Topical Compositions with Cannabis Extracts
US20150297653A1 (en) * 2014-04-17 2015-10-22 Gary J. Speier Pharmaceutical composition and method of manufacturing
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147777B1 (en) 2017-06-16 2021-10-19 Charlotte's Web, Inc. Methods and formulations for efficacious pain relief by transdermal delivery of cannabidiol
US20220257482A1 (en) * 2018-01-13 2022-08-18 TRUETIVA, Inc. Anti-aging and skin tone lightening compositions and methods for same
WO2020028875A1 (fr) * 2018-08-02 2020-02-06 DIVIOS, LLC (a California Limited Liability Company) Composition d'écran solaire renfermant des extraits de cannabis
US11116730B2 (en) 2019-06-28 2021-09-14 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
US11723880B2 (en) 2019-06-28 2023-08-15 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
US12390480B2 (en) 2019-06-28 2025-08-19 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
WO2021016612A1 (fr) * 2019-07-25 2021-01-28 Hempvana, Llc Médicament enrobé de chanvre ou d'un autre cannabinoïde
US20220249585A1 (en) * 2019-07-25 2022-08-11 Hempvana, Llc Medication coated with hemp or other cannabinoid
WO2021116808A1 (fr) * 2019-12-10 2021-06-17 Avicanna Inc. Composition topique de soin de la peau et méthodes de traitement de l'eczéma
WO2021164054A1 (fr) * 2020-02-17 2021-08-26 植物医生(广东)生物科技有限公司 Application de cannabidiol dans la préparation de produits de soin de la peau ayant des effets apaisants et anti-irritation
CN111297711A (zh) * 2020-02-17 2020-06-19 植物医生(广东)生物科技有限公司 一种大麻二酚在制备具有舒缓抗刺激功效的护肤制品、保健品或食品中的应用
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023053043A1 (fr) * 2021-09-28 2023-04-06 Impactive Holdings Ltd. Compositions topiques à base de cannabinoïdes pour soulager la douleur
WO2023105226A1 (fr) * 2021-12-07 2023-06-15 Vive Skincare Limited Compositions de soins de la peau

Also Published As

Publication number Publication date
US20190255014A1 (en) 2019-08-22
CA3081755A1 (fr) 2018-05-11

Similar Documents

Publication Publication Date Title
WO2018085794A1 (fr) Formulations de cannabinoïdes thérapeutiques et procédés pour leur utilisation
CA3093414C (fr) Administration transdermique et/ou dermique d'agents actifs lipophiles
AU2005201042A1 (en) Anhydrous topical skin preparations
AU2018221880B2 (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
KR101443927B1 (ko) 헥사미딘류 및 레티노이드류를 함유하는 피부 개선 조성물
US20210322338A1 (en) Compositions comprising cbd for treating dermatological conditions
CN110709077A (zh) 皮肤治疗方法
US20240009207A1 (en) Cannabidiol (cbd) based composition and method for treating pain
US20040157936A1 (en) Anhydrous topical skin preparations
HK1224198A1 (zh) 包含胆汁酸- 脂肪酸缀合物的抗老化组合物
US20220273559A1 (en) Cbd formulations and uses thereof
US20220151952A1 (en) Novel Nano-Formulation of Cannabidiol (CBD) and Other Cannabinoids for Treatment of Skin Diseases
EP2885004B1 (fr) Composition contenant de la dihydroquercétine, de l'alpha-tocophérol et du bisabolol
Chittasupho et al. Stability, permeation, and cytotoxicity reduction of capsicum extract nanoparticles loaded hydrogel containing wax gourd extract
WO2017059447A1 (fr) Formulations de silibinine topique et leurs utilisations
AU2014386711B2 (en) Compositions that assist skin healing and/or maintain skin health
US20160374911A1 (en) Plant extract composition for skin whitening and reducing melanin as well as application thereof
CA2345501A1 (fr) Preparations anhydres topiques pour la peau
WO2021189077A1 (fr) Méthodes de traitement de l'acné
WO2020178830A1 (fr) Extraits d'argan pour le traitement d'affections dermatologiques
HK40008320A (en) Topical silibinin formulations and uses thereofor
HK1205954B (en) Composition comprising dihydroquercetin, alpha-tocopherol and bisabolol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17866751

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17866751

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3081755

Country of ref document: CA